SOLV vs COO vs BDX vs EW vs SYK

For growth investors, Edwards Lifesciences Corporation (EW) is the stronger pick with 11.

5% revenue growth year-over-year, versus 0. 9% for Solventum Corporation (SOLV). Solventum Corporation (SOLV) offers the better valuation at 8. 1x trailing P/E (11. 2x forward), making it the more compelling value choice. Analysts rate Solventum Corporation (SOLV) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Solventum Corporation (SOLV) is the cheapest at 8.

1x versus Edwards Lifesciences Corporation at 45. 2x. On forward P/E, Solventum Corporation is actually cheaper at 11. 2x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Becton, Dickinson and Company wins at 0. 72x versus Edwards Lifesciences Corporation's 3. 75x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Stryker Corporation (SYK) delivered a total return of +21.

5%, compared to -39. 5% for The Cooper Companies, Inc. (COO). Over 10 years, the gap is even starker: SYK returned +179. 2% versus SOLV's -8. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Stryker Corporation (SYK) is the lower-risk stock at 0.

52β versus Solventum Corporation's 1. 04β — meaning SOLV is approximately 99% more volatile than SYK relative to the S&P 500. On balance sheet safety, Edwards Lifesciences Corporation (EW) carries a lower debt/equity ratio of 7% versus 100% for Solventum Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Edwards Lifesciences Corporation (EW) is pulling ahead at 11.

5% versus 0. 9% for Solventum Corporation (SOLV). On earnings-per-share growth, the picture is similar: Solventum Corporation grew EPS 221. 7% year-over-year, compared to -73. 7% for Edwards Lifesciences Corporation. Over a 3-year CAGR, SYK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Solventum Corporation (SOLV) is the more profitable company, earning 18.

7% net margin versus 7. 7% for Becton, Dickinson and Company — meaning it keeps 18. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EW leads at 27. 0% versus 11. 8% for BDX. At the gross margin level — before operating expenses — EW leads at 78. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Becton, Dickinson and Company (BDX) is the more undervalued stock at a PEG of 0. 72x versus Edwards Lifesciences Corporation's 3. 75x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Solventum Corporation (SOLV) trades at 11. 2x forward P/E versus 26. 6x for Edwards Lifesciences Corporation — 15. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for COO: 53. 6% to $93. 86.

In this comparison, BDX (2.

7% yield), SYK (1. 1% yield) pay a dividend. SOLV, COO, EW do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

52), 1. 1% yield, +179. 2% 10Y return). Both have compounded well over 10 years (SYK: +179. 2%, SOLV: -8. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SOLV is a mid-cap deep-value stock; COO is a mid-cap quality compounder stock; BDX is a mid-cap quality compounder stock; EW is a mid-cap quality compounder stock; SYK is a mid-cap quality compounder stock. BDX, SYK pay a dividend while SOLV, COO, EW do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.